PhRMA Report Shows New Vaccine Development - - BioPharm International

ADVERTISEMENT

PhRMA Report Shows New Vaccine Development



A landmark report on hundreds of new vaccines in development from the Pharmaceutical Research and Manufacturers of America (PhRMA) reflects robust R&D in this field. Biopharmaceutical companies are developing 271 vaccines, about half of them to prevent infectious diseases, and smaller numbers targeted at allergies, neurological disorders, and other conditions, according to the report. A big-growth area is in therapeutic vaccines to treat cancer by boosting the body’s immune response to halt tumor growth, as with test vaccines to treat metastatic renal cell cancer and melanoma. Other new vaccines in development aim to combat a common form of genital herpes, and reports from Africa cite huge drops meningitis cases following introduction of the MenAfriVac therapy in 2010. Similarly, broader use of vaccines against HPV (human papillomavirus) has greatly cut US infection rates in teenage girls.

More vaccine development means expansion of manufacturing capability. Merck continues to expand and upgrade vaccine production despite major corporate cutbacks, as seen in recent FDA approval a plant in Durham, NC to manufacture bulk varicella for vaccines against chicken pox and shingles.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here